Codexis Names Nicholas Green President, Codexis Pharmaceuticals

REDWOOD CITY, Calif., Jan. 17 /PRNewswire/ -- Codexis, Inc., a leading developer of clean manufacturing processes, today announced the appointment of Nicholas Green to the newly-created position of President, Codexis Pharmaceuticals. He will report to Alan Shaw, Ph.D., President and CEO.

Mr. Green will be responsible for management and operations of Codexis Pharmaceuticals, including the products and services for innovator and generics pharmaceutical companies. Codexis Pharmaceuticals provides both innovator and generics pharmaceutical manufacturers with green technology to improve manufacturing cost and purity and reduce waste produced by traditional chemistry approaches to manufacturing.

"We are very pleased to add an experienced pharmaceuticals operations executive to our senior management team," Dr. Shaw said. "Biocatalysis technology is becoming an integral part of today's pharmaceutical manufacturing process development, driven in large part by advances at Codexis. As we have expanded our products and services through internal development and acquisition, our Pharmaceuticals business has grown rapidly. With more than 20 years operating management experience in the global pharmaceuticals and chemicals industries, Nick Green will make an immediate contribution to managing and building this important business."

Mr. Green was previously CEO and Managing Director of Shasun Pharma Solutions, Ltd. Prior to Shasun, he served as President and CEO of Rhodia Pharma Solutions, with responsibility for the Prescription Health and Consumer Health businesses. He has also held operating management positions with chemical and life sciences companies including Clariant Life Sciences, NIPA Biocides and Hodgson Chemicals. Mr. Green holds a bachelor's degree in chemistry from London University, Queen Mary College and an MBA from Huddersfield University in the United Kingdom.

Codexis, Inc., a clean technology company, is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. These technologies enable novel solutions for efficient, cost-effective and environmentally-friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the U.S. EPA recognized Codexis with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information, please visit http://www.codexis.com.

Contact: Justin Jackson, [email protected], Burns McClellan, 212-213-0006, or Lyn Christenson, [email protected], 650-421-8144.

SOURCE Codexis, Inc.

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.